Associated material
Tools
- Sign up for article alerts
- Download references
- Download XML
- Email to a friend
- Order reprints
- Post a comment
Citeulike
Connotea
Del.icio.us
Facebook
Mendeley
Twitter
The role of animal models in advancing amyloid-beta immunotherapy to the clinic
-
* Corresponding author: Dora Games Dora.Games@neotopebio.com
Janssen Alzheimer Immunotherapy Research and Development, LLC, 700 Gateway, Blvd, South San Francisco, CA 94080, USA
Alzheimer's Research & Therapy 2010, 2:22 doi:10.1186/alzrt46
Published: 29 July 2010Abstract
The amyloid-beta (Aβ) hypothesis of Alzheimer's disease (AD) causality is now well into its third decade and is finally entering a phase of rigorous clinical testing in numerous late stage clinical trials. The use of Aβ-based animal models of AD has been essential to the discovery and/or preclinical validation of many of these therapeutic approaches. While several neuropathologically based results from preclinical studies have translated nicely into AD patients, the full clinical value of Aβ-directed therapies awaits results from trials now in progress.